Ares Q3 Lands: Street Splits on Targets After Earnings Beat

ARES closed the week at $128.15, up 5% on the week, as investors absorbed a Q3 earnings release that landed on October 30 and set off an immediate wave of analyst target revisions pulling in opposite directions.

Thursday's print delivered the data point the market had been waiting for since Q1's miss. The stock gained 3.5% on the day after the release, its best single-session reaction in recent quarters. That move narrowed the gap to the analyst consensus mean of $144.85, though at roughly 13% below that level, the Street's expectations still sit meaningfully above where the stock is trading today.

The analyst response to the print was the most active story of the week. Six firms updated targets on October 30 alone, and the moves illustrate a genuinely divided Street. RBC raised its target to $171, Barclays lifted to $151, and Wells Fargo moved to $141, all maintaining positive ratings and signalling that the Q3 numbers were enough to rebuild conviction. JP Morgan, despite keeping its Overweight, trimmed one dollar to $154, and TD Cowen made a similarly marginal cut to $158. The contrast is not between bulls and bears on the rating, almost every firm active on the name sits at Outperform or Overweight, but on how aggressively they are willing to price in the growth trajectory. KBW's Market Perform at $130 is the outlier, sitting barely above the current share price and implying that the recovery still has to be earned.

The bull case rests on the scale of the franchise: $671.3 billion of total AUM and $409.9 billion of fee-earning AUM, with management pointing to a 16% to 20% FRE compound growth target into 2028. Forward earnings momentum is one of the stronger signals in the factor data, with the 12-month forward EPS year-on-year increase reading ranking in the 91st percentile of the universe. The bear case has not disappeared. Q1 saw after-tax realised net income of $1.24 per share against estimates of $1.37, and performance fees and management fees both fell short. Thursday's numbers are what the market is repricing now, but that Q1 miss set a low bar for credibility that Q3 either clears or underscores.

Positioning does not reflect a heavily contested stock. Short interest is 7.3% of free float, around 15.9 million shares, and has crept up 4.5% on the week, the first meaningful move higher after months of sideways drift. The borrow market remains comfortable. Availability has tightened to 255% from 301% a week ago, moving in the right direction for bears to add, but still indicating more than two shares available for every one currently lent out. The cost to borrow rose 18% on the week to 0.54%, but that is against a base so low that the absolute level remains trivial. The ORTEX short score has edged to 60.4 from 57.9 ten days ago, modest upward pressure but nowhere near a reading that signals a coordinated short-side thesis. Options are the one signal worth flagging. The put/call ratio hit 2.57 on Friday, more than two standard deviations above the 20-day mean of 2.46, a level of defensive positioning that is unusually elevated for a stock that just posted a day of positive price action. That divergence, buyers in the stock, hedgers in the options market, is the tension most worth watching.

Peer context is helpful here. OWL gained 10.4% on the week, the strongest performer in the alternative asset manager group. TPG added 4.6% and CG 4.1%, broadly in line with ARES's 5% gain. BX lagged at just 0.5%, suggesting the week's move in ARES was sector-driven but not exceptional, consistent with a result that reassured rather than surprised.

The next earnings event is flagged for February 5, 2027, giving 97 days for the Street to calibrate whether Thursday's Q3 numbers represent a durable inflection or another quarter that passes without closing the gap between the consensus target and where the stock actually trades.